Companies

Reagene Innovations teams up with Tech Mahindra, INDRAS to identify Covid treatment drugs

Our Bureau Hyderabad | Updated on May 21, 2020 Published on May 21, 2020

Reagene Innovations, incubated at ASPIRE-BioNEST, University of Hyderabad (UoH) along with INDRAS Pvt Ltd, Hyderabad is collaborating with Tech Mahindra to identify FDA-approved drugs which can be redeployed as therapeutics for Covid-19.

The collaboration will use both artificial intelligence and rational computational approaches for identifying approved existing drugs, validated using biological and pharmacological methods.

The objective of their collaboration is to stop the entry of the virus into the lung airway epithelial cells. The choice of this strategy is important, because the high transmission rate of Covid-19 is attributed in part to tight attachment of the virus, that facilitates its entry into lung cells. Once the virus is stopped from entering the cells, it is rendered harmless.

Reagene Innovations, a biotech start-up co-founded by Uday Saxena and Subramanyam Vangala, will create a human vascular lung model to study Covid-19 using 3D bioprinting technique. This new technique is being used to create human organs and tissues.

Ratnakar Palakodeti, Vice-President of Life Sciences vertical of Tech Mahindra, said, “this collaboration will bring valuable findings in therapeutic interventions through a faster route than conventional drug discovery as well as add invaluable intellectual property”.

Published on May 21, 2020

A letter from the Editor


Dear Readers,

The coronavirus crisis has changed the world completely in the last few months. All of us have been locked into our homes, economic activity has come to a near standstill. Everyone has been impacted.

Including your favourite business and financial newspaper. Our printing and distribution chains have been severely disrupted across the country, leaving readers without access to newspapers. Newspaper delivery agents have also been unable to service their customers because of multiple restrictions.

In these difficult times, we, at BusinessLine have been working continuously every day so that you are informed about all the developments – whether on the pandemic, on policy responses, or the impact on the world of business and finance. Our team has been working round the clock to keep track of developments so that you – the reader – gets accurate information and actionable insights so that you can protect your jobs, businesses, finances and investments.

We are trying our best to ensure the newspaper reaches your hands every day. We have also ensured that even if your paper is not delivered, you can access BusinessLine in the e-paper format – just as it appears in print. Our website and apps too, are updated every minute, so that you can access the information you want anywhere, anytime.

But all this comes at a heavy cost. As you are aware, the lockdowns have wiped out almost all our entire revenue stream. Sustaining our quality journalism has become extremely challenging. That we have managed so far is thanks to your support. I thank all our subscribers – print and digital – for your support.

I appeal to all or readers to help us navigate these challenging times and help sustain one of the truly independent and credible voices in the world of Indian journalism. Doing so is easy. You can help us enormously simply by subscribing to our digital or e-paper editions. We offer several affordable subscription plans for our website, which includes Portfolio, our investment advisory section that offers rich investment advice from our highly qualified, in-house Research Bureau, the only such team in the Indian newspaper industry.

A little help from you can make a huge difference to the cause of quality journalism!

Support Quality Journalism
  1. Comments will be moderated by The Hindu Business Line editorial team.
  2. Comments that are abusive, personal, incendiary or irrelevant cannot be published.
  3. Please write complete sentences. Do not type comments in all capital letters, or in all lower case letters, or using abbreviated text. (example: u cannot substitute for you, d is not 'the', n is not 'and').
  4. We may remove hyperlinks within comments.
  5. Please use a genuine email ID and provide your name, to avoid rejection.
You have read 1 out of 3 free articles for this week. For full access, please subscribe and get unlimited access to all sections.